Dendreon to close plant and make layoffs as it tackles Provenge slip
This article was originally published in Scrip
Executive Summary
Dendreon will close a manufacturing plant in Morris Plains, New Jersey in the US and cut 600 jobs as it strengthens its sales team in the face of a 2.4% decline in revenue between the first and second quarters of 2012 from its sole product Provenge (sipuleucel-T), an autologous cellular immunotherapy for asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer.
You may also be interested in...
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.